Logo

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as Monotherapy for Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors

Share this

Merck's Keytruda (pembrolizumab) Receives the US FDA's Approval as Monotherapy for Patients with Unresectable or Metastatic Tumor Mutational Burden-High Solid Tumors

Shots:

  • The accelerated approval is based on KEYNOTE-158 study assessing Keytruda (200mg- q3w). In a study- 1-050 patients were included in the efficacy analysis population in which TMB was analyzed in the subset of 790 patients with sufficient tissue for testing based on protocol-specified testing requirements- out of 790- 102 had tumors identified as TMB-H- defined as TMB ≥10 mut/Mb
  • Results: In patients whose tumors were TMB-H- ORR (29%); CR (4%); PR (25%); after a median follow-up time of 11.1 mos. mDOR (not reached). In a pre-specified analysis of patients with TMB ≥13 mut/Mb: ORR (37%); CR (3%); PR (34%)- In an exploratory analysis in 32 patients whose cancer had TMB ≥10 mut/Mb & <13 mut/Mb- the ORR (13%); median duration of exposure (4.9mos.)
  • The FDA also approved FoundationOne CDx test as the companion diagnostic to identify patients with solid tumors that are TMB-H (≥10 mutations/ megabase) who may benefit from immunotherapy treatment with Keytruda monotherapy

Click here to read full press release/ article 

Ref: Buinesswire | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions